Pfizer-BioNTech Booster Shot Restores Full Covid Protection
- Trial was run in period when delta was dominant Covid strain
- Results may strengthen case for giving third doses more widely
This article is for subscribers only.
Pfizer Inc. and BioNTech SE said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely.
A booster was 95.6% effective against symptomatic Covid in the study, which followed 10,000 people aged 16 and older, the companies said in a statement Thursday. The fast-spreading delta variant was the predominate strain during the trial.